Corpus ID: 54191336

��inica� ��� and��chani��� o� In�i�i�a� �r�at��nt on In�a��ator� Bo��� �i��a��� A ��c�nt �pdat�

  title={��inica� ��� and��chani��� o� In�i�i�a� �r�at��nt on In�a��ator� Bo��� �i��a��� A ��c�nt �pdat�},
  author={Y. S. Guo and Nonghua Lu and Aiping Bai},
e pathogenesis and treatment of in�ammatory bowel disease (IBD) have been recently advanced, while it is still challenged with high morbidity and poor prognosis. In�iximab, a monoclonal antibody of tumor necrosis factor (TNF), has emerged as an e�cient treatment with many clinical bene�ts such as quick disease activity reduction and IBD patient life quality improvement. However, the biological effects of in�iximab on IBD need to be elucidated. is paper reviewed the clinical use and recently… Expand

Tables from this paper


Risk of Infection and Prevention in Pediatric Patients With IBD: ESPGHAN IBD Porto Group Commentary
A commentary on infection prophylaxis for the pediatric age group is presented to present a commentary on infections in pediatric IBD as well as the European Crohn's and Colitis Organization guidelines. Expand
Optimizing anti-TNF treatment in inflammatory bowel disease.
Trial data suggest that systematic maintenance with 8 weekly doses of infliximab decreases the rate of complications, hospitalizations, and surgeries and these effects probably are achieved thanks to thorough healing of the bowel. Expand
Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn’s disease
It is demonstrated that apoptosis is the major mechanism by which infliximab exerts its killing activity on LPT in Crohn’s disease, and the sustained LPT proapoptotic action of inflIXimab, which extends far beyond its circulating half life, may be responsible for the sustained remission induced in Cro bowel disease patients by inflixIMab retreatment. Expand
Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease
Inhibiting the proinflammatory cytokine tumor necrosis factor dramatically reduces gut inflammation and largely restores the gut barrier in Crohn's disease, confirming the central role of TNF in gut barrier modulation in inflammatory conditions in vivo. Expand
Cytokine and anti-cytokine therapies for inflammatory bowel disease.
Recent advances in the understanding of the pathophysiological conditions of IBD have provided new immune system modulators as therapeutic tools, and those immune therapies will provide new insights into cell-based and gene-based treatment against IBD in near future. Expand
New cytokine therapeutics for inflammatory bowel disease.
The conventional drug thalidomide and possibly MAP-kinase inhibitors may become novel treatment entities for IBD. Expand
Human Antichimeric Antibody in Children and Young Adults with Inflammatory Bowel Disease Receiving Infliximab
In children and adolescents with IBD, HACA formation is related to IR and to the duration of response to treatment and immunomodulatory agents seem to have a protective role against development of HACA or high titers of antibodies. Expand
Anti tumour necrosis‐α therapy increases the number of FOXP3+ regulatory T cells in children affected by Crohn’s disease
It is suggested that anti TNF‐α immunotherapy can also restore mucosal homeostasis in Crohn’s disease and affects activation and possibly expansion of mucosal regulatory T cells. Expand
Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect.
This is the first case of psoriasis induced first by infliximab and later by adalimumab in the same CD patient, and the reason for this apparently paradoxical effect of the therapy is still unclear. Expand
Role of cytokines in the pathogenesis of inflammatory bowel disease.
Treatment of IBD may include combination or sequential cytokine and anticytokine administration in defined groups of patients based on their mucosal cytokine profiles, and treatment with recombinant human interleukin-10 has been beneficial in Crohn's disease but not in ulcerative colitis. Expand